Metastatic colorectal cancer: advances in biochemical modulation and new drug development.
Meropol
N J
NJ
Division of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.
Creaven
P J
PJ
Petrelli
N J
NJ
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000378:metabolism* / Q000627:therapeutic use*; D001224:Aspartic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives; D002945:Cisplatin / Q000031:analogs & derivatives; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D003967:Diarrhea / Q000139:chemically induced / Q000188:drug therapy; D004064:Digestive System / Q000187:drug effects; D004334:Drug Administration Schedule; D005472:Fluorouracil / Q000008:administration & dosage / Q000378:metabolism; D005765:Gastrointestinal Agents / Q000627:therapeutic use; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage; D002955:Leucovorin / Q000008:administration & dosage; D015282:Octreotide / Q000627:therapeutic use; D010746:Phosphonoacetic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives; D011355:Prodrugs / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D013940:Thymidylate Synthase / Q000037:antagonists & inhibitors; D059004:Topoisomerase I Inhibitors
D005765:Gastrointestinal Agents; D016898:Interferon-alpha; D011355:Prodrugs; D059004:Topoisomerase I Inhibitors; D016179:Granulocyte Colony-Stimulating Factor; D001224:Aspartic Acid; C013195:sparfosic acid; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D013940:Thymidylate Synthase; D010746:Phosphonoacetic Acid; D002945:Cisplatin; D002955:Leucovorin; D015282:Octreotide; D005472:Fluorouracil